Ref ID: 15160
Author:
T. PELíEZ, C. PADILLA, B. GAMA, P. ESCRIBANO, E. REIGADAS, P. LOPEZ ROA, A. ESPINEL-INGROFF, R. FLORES, J. GUINEA, P. MUí‘OZ, E. BOUZA
Author address:
1Hosp. Gregorio Marañón. Univ. of Madrid, Madrid, Spain, 2VCU Med. Ctr., Richmond, VA.
Full conference title:
50th Annual ICAAC
Date: 12 September 2014
Abstract:
Background: Aspergillus section Usti are a rare group of pathogens that can cause invasive infections in immunocompromised hosts. We studied the epidemiology and antifungal susceptibility of A. section Usti. Methods: A. section Usti strains (2003 to February 2010) were analyzed. Charts were reviewed for clinical data (eg, underlying disease, antifungal therapy, outcome). Strains were identified by PCR amplification of β -tubulin. Antifungal susceptibility to amphotericin B (AMB), itraconazole (IZ), voriconazole (VZ), caspofungin (CAS), anidulafungin (AND), micafungin (MF), and terbinafine (TB) was determined by CLSI M38-A2. Results: We recovered 34 isolates of A. section Usti:( 22 clinical [14 pts] & 12 environmental from hospital areas). Clinical isolates belonged to A. calidoustus (11), A. insuetus (1), A. pseudodeflectus (1), & A. puniceus (1); environmental isolates belonged to A. puniceus (6), A. calidoustus (5), & A. pseudodeflectus (1). Global MIC ranges (µg/ml) of the isolates were AMB (0.25-4), IZ (2-32), VZ (2-8), CAS (0.06-4), AND (0.007-2), MF (0.06-0.25), & TB (0.06-0.25). The geometric mean/MIC90 (µg/ml) was AMB (2.31/4), IZ (7.84/16), VZ (4.33/8), CAS (0.37/4), AND (0.03/0.25), MF (0.07/0.125) and TB (0.09/0.125). Of 14 pts with ≥ 1 isolates of A. section Usti, 12 were only colonized (11 COPD pts), & the other 2 pts had probable aspergillosis (pulmonary tuberculosis and hematopoietic stem cell transplant). Conclusions: This is one of the largest A. section Usti studies. Isolates were resistant to azoles and decreased susceptibility to amphotericin B. The activity of echinocandins was variable. Microbiology departments must be aware that A. section Usti may be resistant to one or more of the antifungal agents used to treat invasive aspergillosis.
Abstract Number: M-376
Conference Year: 2010
Link to conference website: NULL
New link: NULL
Conference abstracts, posters & presentations
-
Title
Author
Year
Number
Poster
-
v
Teclegiorgis Gebremariam [MS]1, Yiyou Gu [PhD]1, Sondus Alkhazraji [PhD]1, Jousha Quran1, Laura K. Najvar [BS]2, Nathan P. Wiederhold [PharmD]2, Thomas F. Patterson [MD]2, Scott G. Filler [MD]1,3, David A. Angulo (MD)4, Ashraf S. Ibrahim [PhD]1,3*,
2024
91
n/a
-
v
Ruta Petraitiene (US)
2024
90
n/a
-
v
Fabio Palmieri (CH), Junier Pilar
2024
89
n/a
-
v
Evelyne Côté (CA)
2024
88
n/a
-
v
Eliane Vanhoffelen (BE)
2024
87
n/a
-
v
Teclegiorgis Gebremariam, Yiyou Gu, Eman Youssef, Sondus Alkhazraji, Joshua Quran, Nathan P. Wiederhold, Ashraf S. Ibrahim
2024
86
n/a
-
v
Thomas Orasch (DE)
2024
85
n/a
-
v
Julien Alex, Katherine González, Gauri Gangapurwala, Antje Vollrath, Zoltán Cseresnyés, Christine Weber, Justyna A. Czaplewska, Stephanie Hoeppener, Carl-Magnus Svensson, Thomas Orasch, Thorsten Heinekamp, Carlos Guerrero-Sánchez, Marc Thilo Figge, Ulrich S. Schubert, Axel A. Brakhage
2024
84
n/a
-
v
Vasireddy Teja, Bibhuti Saha Hod, Soumendranath Haldar (IN)
2024
83
n/a
-
v
Vasireddy Teja, Bibhuti Saha Hod, Soumendranath Haldar (IN)
2024
82
n/a